Jazz Pharmaceuticals PLC $ 126.35 0.27 (0.21%)
Volume:
523,037
Avg Vol (1m):
690,223
Market Cap $:
7.01 Bil
Enterprise Value $:
7.57 Bil
P/E (TTM):
54.70
P/B:
2.23
Financial Strength | 5/10 |
| Current | Vs Industry | Vs History | |
|---|---|---|---|
| Cash-To-Debt | 0.75 | ||
| Equity-to-Asset | 0.52 | ||
| Debt-to-Equity | 0.72 | ||
| Debt-to-EBITDA | 3.91 | ||
| Interest Coverage | 7.37 | ||
| Piotroski F-Score | 7 | ||
| Altman Z-Score | 2.48 | ||
| Beneish M-Score | -2.79 | ||
| WACC vs ROIC | |||
Profitability Rank | 9/10 |
| Current | Vs Industry | Vs History | |
|---|---|---|---|
| Operating Margin % | 26.89 | ||
| Net Margin % | 6.01 | ||
| ROE % | 4.41 | ||
| ROA % | 2.39 | ||
| ROC (Joel Greenblatt) % | 43.62 | ||
| 3-Year Revenue Growth Rate | 16 | ||
| 3-Year EBITDA Growth Rate | 10.8 | ||
| 3-Year EPS without NRI Growth Rate | 12.3 |
Valuation Rank | 9/10 |
| Current | Vs Industry | Vs History | |
|---|---|---|---|
| PE Ratio | 54.72 | ||
| Forward PE Ratio | 10.04 | ||
| PE Ratio without NRI | 54.72 | ||
| Price-to-Owner-Earnings | 54.46 | ||
| PB Ratio | 2.23 | ||
| PS Ratio | 3.25 | ||
| Price-to-Free-Cash-Flow | 15.05 | ||
| Price-to-Operating-Cash-Flow | 8.1 | ||
| EV-to-EBIT | 38.27 | ||
| EV-to-EBITDA | 13.11 | ||
| EV-to-Revenue | 3.44 | ||
| PEG Ratio | 2.76 | ||
| Shiller PE Ratio | 25.98 | ||
| Current Ratio | 5.62 | ||
| Quick Ratio | 5.39 | ||
| Days Inventory | 234.75 | ||
| Days Sales Outstanding | 57.95 | ||
| Days Payable | 148 |
Dividend & Buy Back |
| Current | Vs Industry | Vs History | |
|---|---|---|---|
| 3-Year Average Share Buyback Ratio | 2.1 |
Valuation & Return |
| Current | Vs Industry | Vs History | |
|---|---|---|---|
| Price-to-Intrinsic-Value-Projected-FCF | 0.76 | ||
| Price-to-Intrinsic-Value-DCF (Earnings Based) | 5.11 | ||
| Price-to-Median-PS-Value | 0.51 | ||
| Price-to-Peter-Lynch-Fair-Value | 7.18 | ||
| Earnings Yield (Greenblatt) % | 2.61 | ||
| Forward Rate of Return (Yacktman) % | 14.6 |